Search research articles
Contact Us
Filters
Showing results (181-190 of 244) with videos related to
Page
of 25
Sort By:
Blood
|
August 18, 2022
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML
Maike Roas, Binje Vick, Marc-André Kasper, et al.
Gastroenterology
|
February 15, 2026
STING ablation in T cells is required for the efficacy of STING agonists in CAR-T cell immunotherapy of pancreatic cancer
Ignazio Piseddu, Rebekka Endres, Fabian Lanzl, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 26, 2023
Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy
Jiaqi Fan, Anne Adams, Noëlle Sieg, et al.
Blood Advances
|
October 7, 2022
Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy
Hannah Reimann, Anita N Kremer, Viktoria Blumenberg, et al.
Plos Pathogens
|
October 6, 2021
Impaired function and delayed regeneration of dendritic cells in COVID-19
Elena Winheim, Linus Rinke, Konstantin Lutz, et al.
Hemasphere
|
December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
Jesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Hemasphere
|
July 1, 2024
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells
Gloria Iacoboni, Mario A Sánchez-Salinas, Kai Rejeski, et al.
Hemasphere
|
July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
Veit Bücklein, Ariel Perez, Kai Rejeski, et al.
Intensive Care Medicine
|
June 30, 2026
The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis
Michael Ruzicka, Hans Christian Stubbe, Josia Fauser, et al.
Blood
|
June 12, 2016
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Klaus H Metzeler, Tobias Herold, Maja Rothenberg-Thurley, et al.
Page
of 25
Search research articles
Search
Showing results (181-190 of 244) with videos related to
Sort By:
Page
of 25
Blood
|
August 18, 2022
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML
Maike Roas, Binje Vick, Marc-André Kasper, et al.
Gastroenterology
|
February 15, 2026
STING ablation in T cells is required for the efficacy of STING agonists in CAR-T cell immunotherapy of pancreatic cancer
Ignazio Piseddu, Rebekka Endres, Fabian Lanzl, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
February 26, 2023
Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy
Jiaqi Fan, Anne Adams, Noëlle Sieg, et al.
Blood Advances
|
October 7, 2022
Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy
Hannah Reimann, Anita N Kremer, Viktoria Blumenberg, et al.
Plos Pathogens
|
October 6, 2021
Impaired function and delayed regeneration of dendritic cells in COVID-19
Elena Winheim, Linus Rinke, Konstantin Lutz, et al.
Hemasphere
|
December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
Jesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Hemasphere
|
July 1, 2024
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells
Gloria Iacoboni, Mario A Sánchez-Salinas, Kai Rejeski, et al.
Hemasphere
|
July 14, 2023
Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use
Veit Bücklein, Ariel Perez, Kai Rejeski, et al.
Intensive Care Medicine
|
June 30, 2026
The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis
Michael Ruzicka, Hans Christian Stubbe, Josia Fauser, et al.
Blood
|
June 12, 2016
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Klaus H Metzeler, Tobias Herold, Maja Rothenberg-Thurley, et al.
Page
of 25